Emerging Infectious Disease ISSN: 1080-6059

Borrelia burgdorferi Infection and Cutaneous Lyme Disease, Mexico

Guadalupe Gordillo-Pérez*, Javier Torres*, Fortino Solórzano-Santos*, Sylvie de Martino†, Dan Lipsker†, Edmundo Velázquez*, Guillermo Ramon*, Muñoz Onofre*, and Benoit Jaulhac†

Author affiliations: *Instituto Mexicano del Seguro Social, Mexico City, Mexico; †Hôpitaux Universitaires, Strasbourg, France;

Main Article

Appendix Figure

Molecular evidence for Borrelia infection. A) PCR for fla gene from Borrelia burgdorferi sensu lato; B) Southern blot assay with probes specific for B. burgdorferi sensu stricto; C) Sequences of fla gene amplified from 2 patients with erythema migrans (lines 1 and 2) and 1 with lymphocytoma (line 3) and aligned with the sequence of the fla gene from B. burgdorferi sensu stricto strain B31;and D) Sequence of the osp A gene amplified from a patient with erythema migrans (line 1) and aligned with the ospA gene from B. burgdorferi sensu stricto strain B31.

Appendix Figure. Molecular evidence for Borrelia infection. A) PCR for fla gene from Borrelia burgdorferi sensu lato; B) Southern blot assay with probes specific for B. burgdorferi sensu stricto; C) Sequences of fla gene amplified from 2 patients with erythema migrans (lines 1 and 2) and 1 with lymphocytoma (line 3) and aligned with the sequence of the fla gene from B. burgdorferi sensu stricto strain B31;and D) Sequence of the osp A gene amplified from a patient with erythema migrans (line 1) and aligned with the ospA gene from B. burgdorferi sensu stricto strain B31.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.